Literature DB >> 18684965

Vaccination without autoantigen protects against collagen II-induced arthritis via immune deviation and regulatory T cells.

Irina Kochetkova1, Theresa Trunkle, Gayle Callis, David W Pascual.   

Abstract

Anti-inflammation immunotherapy has been successfully applied for the treatment of autoimmune diseases. Mucosal vaccines against autoimmune disorders are beneficial by influencing the regulatory compartment of gut and systemic adaptive immune systems. A Salmonella vector expressing colonization factor Ag I (CFA/I), shown to behave as an anti-inflammatory vaccine, stimulates the production of CD4(+)CD25(+) T cells and regulatory cytokines. In this work, we queried whether Salmonella-CFA/I can protect DBA/1 mice from collagen-induced arthritis. The incidence of arthritis and cartilage loss in vaccinated DBA/1 mice was remarkably lower when compared with unprotected mice. Clinical findings were accompanied by the suppression of inflammatory cytokines TNF-alpha, IL-1beta, IL-6, and IL-27. Vaccination evoked a multi-tier response consisting of IL-4 producing Th2 cells, an increased production of TGF-beta by CD4(+) T cells, and suppression of collagen II-specific CD4(+) T cell proliferation. To assess the contribution of Salmonella-CFA/I-primed CD4(+) T cells, adoptive transfer studies with total CD4(+), CD4(+)CD25(-), or CD4(+)CD25(+) T cells were performed 15 days postchallenge. Mice receiving either subset showed reduced disease incidence and low clinical scores; however, mice receiving total CD4(+) T cells showed delayed disease onset by 10 days with reduced clinical scores, reduced IL-17 and IL-27, but enhanced IL-4, IL-10, IL-13, and TGF-beta. Inhibition of TGF-beta or IL-4 compromised protective immunity. These data show that Salmonella-CFA/I vaccination of DBA/1 mice protects against collagen-induced arthritis by stimulating TGF-beta- and IL-4-producing regulatory CD4(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684965      PMCID: PMC2599931          DOI: 10.4049/jimmunol.181.4.2741

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

1.  B cell-deficient mice do not develop type II collagen-induced arthritis (CIA).

Authors:  L Svensson; J Jirholt; R Holmdahl; L Jansson
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

2.  Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice.

Authors:  K Vermeire; H Heremans; M Vandeputte; S Huang; A Billiau; P Matthys
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

3.  WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection.

Authors:  H Yoshida; S Hamano; G Senaldi; T Covey; R Faggioni; S Mu; M Xia; A C Wakeham; H Nishina; J Potter; C J Saris; T W Mak
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

4.  Immune responses to novel Escherichia coli and Salmonella typhimurium vectors that express colonization factor antigen I (CFA/I) of enterotoxigenic E. coli in the absence of the CFA/I positive regulator cfaR.

Authors:  S Wu; D W Pascual; J L VanCott; J R McGhee; D R Maneval; M M Levine; D M Hone
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

5.  Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment.

Authors:  W B van den Berg; L A Joosten; M Helsen; F A van de Loo
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

6.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

Authors:  R O Williams; M Feldmann; R N Maini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

7.  Type II collagen in cartilage evokes peptide-specific tolerance and skews the immune response.

Authors:  V Malmström; P Kjellén; R Holmdahl
Journal:  J Autoimmun       Date:  1998-06       Impact factor: 7.094

8.  Systemic versus cartilage-specific expression of a type II collagen-specific T-cell epitope determines the level of tolerance and susceptibility to arthritis.

Authors:  V Malmström; E Michaëlsson; H Burkhardt; R Mattsson; E Vuorio; R Holmdahl
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

9.  Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen.

Authors:  K Terato; D S Harper; M M Griffiths; D L Hasty; X J Ye; M A Cremer; J M Seyer
Journal:  Autoimmunity       Date:  1995       Impact factor: 2.815

10.  Oral immunization with a Salmonella typhimurium vaccine vector expressing recombinant enterotoxigenic Escherichia coli K99 fimbriae elicits elevated antibody titers for protective immunity.

Authors:  M A Ascón; D M Hone; N Walters; D W Pascual
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

View more
  23 in total

1.  Coming of AGE: facile generation of attenuated vaccine strains through heterologous gene expression.

Authors:  Carlos C Goller; Patrick C Seed
Journal:  Virulence       Date:  2012-01-01       Impact factor: 5.882

2.  Segregated regulatory CD39+CD4+ T cell function: TGF-β-producing Foxp3- and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis.

Authors:  Irina Kochetkova; Theresa Thornburg; Gayle Callis; David W Pascual
Journal:  J Immunol       Date:  2011-10-03       Impact factor: 5.422

3.  Expression of Escherichia coli virulence usher protein attenuates wild-type Salmonella.

Authors:  Xinghong Yang; Zhiyong Suo; Theresa Thornburg; Kathryn Holderness; Ling Cao; Timothy Lim; Nancy Walters; Laura Kellerman; Linda Loetterle; Recep Avci; David W Pascual
Journal:  Virulence       Date:  2012-01-01       Impact factor: 5.882

4.  Active immunization using a single dose immunotherapeutic abates established EAE via IL-10 and regulatory T cells.

Authors:  Agnieszka Rynda-Apple; Eduardo Huarte; Massimo Maddaloni; Gayle Callis; Jerod A Skyberg; David W Pascual
Journal:  Eur J Immunol       Date:  2010-12-29       Impact factor: 5.532

Review 5.  The microbiome and rheumatoid arthritis.

Authors:  Jose U Scher; Steven B Abramson
Journal:  Nat Rev Rheumatol       Date:  2011-08-23       Impact factor: 20.543

6.  The gut microbiome in multiple sclerosis.

Authors:  Daniel W Mielcarz; Lloyd H Kasper
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

Review 7.  Interleukin-35 in immune-related diseases: protection or destruction.

Authors:  Junfeng Zhang; Yunsheng Zhang; Qingpeng Wang; Chunlei Li; Hongxin Deng; Chuanping Si; Huabao Xiong
Journal:  Immunology       Date:  2019-03-07       Impact factor: 7.397

8.  IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10.

Authors:  Irina Kochetkova; Sarah Golden; Kathryn Holderness; Gayle Callis; David W Pascual
Journal:  J Immunol       Date:  2010-05-10       Impact factor: 5.422

9.  Anti-Inflammatory Effects and Joint Protection in Collagen-Induced Arthritis after Treatment with IQ-1S, a Selective c-Jun N-Terminal Kinase Inhibitor.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Deepa Hammaker; Irina Kochetkova; Andrei I Khlebnikov; Sergey A Lyakhov; Gary S Firestein; Mark T Quinn
Journal:  J Pharmacol Exp Ther       Date:  2015-03-17       Impact factor: 4.030

Review 10.  Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis.

Authors:  Kenneth S Rosenthal; Katalin Mikecz; Harold L Steiner; Tibor T Glant; Alison Finnegan; Roy E Carambula; Daniel H Zimmerman
Journal:  Expert Rev Vaccines       Date:  2015-03-18       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.